Welcome to our dedicated page for Freeline Therapeutics Holdings plc news (Ticker: FRLN), a resource for investors and traders seeking the latest updates and insights on Freeline Therapeutics Holdings plc stock.
Freeline Therapeutics Holdings plc (Nasdaq: FRLN) is a clinical-stage biopharmaceutical company dedicated to developing and commercializing transformative gene therapies for chronic and debilitating diseases. The company's focus lies primarily on gene therapy solutions that address unmet medical needs, utilizing a next-generation AAV gene therapy platform developed by Professor Amit Nathwani, a leading authority in hematology from University College London (UCL).
Freeline's flagship program is FLT201, a highly differentiated gene therapy candidate targeting Gaucher disease type 1. This condition, caused by mutations in the GBA1 gene, leads to a deficiency in the glucocerebrosidase (GCase) enzyme, resulting in harmful substrate accumulation in organs such as the spleen, liver, bone, and lungs. FLT201 employs a rationally engineered longer-acting GCase variant designed to produce sustained enzyme levels and penetrate deeper tissues, potentially halting disease progression and improving patient outcomes with a single treatment. Early clinical data from the GALILEO-1 trial highlight the therapy’s potential, showing substantial reductions in key biomarkers and robust increases in plasma GCase activity.
Building on its work in Gaucher disease, Freeline has initiated a research program targeting GBA1-linked Parkinson’s disease. This program aims to extend the therapeutic benefits of its engineered GCase variant to patients suffering from Parkinson's disease due to GBA1 mutations. These mutations significantly increase the risk of Parkinson’s disease, leading to earlier onset, more severe symptoms, and faster progression to dementia. The preclinical data for this program is promising, showcasing the gene therapy’s enhanced enzyme activity in various cell lines.
Headquartered in the UK, with operations in the United States, Freeline is driven by its commitment to employing innovative gene therapy techniques to provide life-changing treatments. The company leverages proprietary AAVS3 capsid technology and novel promoters and transgenes to deliver functional copies of therapeutic genes to liver cells, ensuring persistent and effective protein expression. Freeline’s pipeline promises significant advancements, with FLT201 leading the charge in ongoing clinical trials and additional programs in the research phase.
Freeline's recent achievements and financial updates reflect its proactive stance in advancing its mission. The company’s financial results for the second quarter of 2023 reveal significant progress and a solid strategic focus, emphasizing the advancement of FLT201 as its top priority. The successful dosing of patients in the GALILEO-1 trial and the unveiling of the GBA1-linked Parkinson’s disease program underline Freeline's relentless pursuit of innovative treatments for genetic disorders.
Freeline Therapeutics Holdings plc (Nasdaq: FRLN) has appointed Mark Baldry as its new Chief Commercial Officer as of November 2, 2020. Baldry brings 30 years of experience in the biopharmaceutical sector, focusing on rare diseases. Previously at Wave Life Sciences and Amicus Therapeutics, he has a solid track record in launching innovative treatments. CEO Theresa Heggie emphasized the significance of this appointment amidst Freeline's transformative year marked by clinical progress and a bolstered management team. The company aims to advance gene therapy for chronic diseases, underlining its commitment to patient care.
Freeline Therapeutics (Nasdaq: FRLN) announced new analytical technologies that evaluate AAV capsids containing full-length vector genomes. This announcement will be presented at the 12th Annual Protein and Antibody Engineering Summit from November 9-13, 2020. Improved analytical technologies aim to enhance the safety and efficacy of Freeline’s gene therapy. CEO Theresa Heggie emphasized the company’s progress in clinical programs for Haemophilia B and Fabry Disease, along with advancements in preclinical programs. The aim is to develop best-in-class capsids for effective treatment.
Freeline Therapeutics (FRLN) reported strong financial results for H1 2020, with cash reserves exceeding $250 million as of September 30. The company has shown positive clinical advancements in its Haemophilia B and Fabry disease programs, demonstrating durable Factor 9 activity. Upcoming milestones include data updates from the B-AMAZE trial expected in Q4 2020 and the initiation of pivotal trials in 2021. Total operating expenses rose to $41.1 million, mainly due to increased research and development costs. The company completed a successful IPO, raising approximately $166.6 million.
Freeline Therapeutics (Nasdaq: FRLN) will have its CEO, Theresa Heggie, present at Chardan’s 4th Annual Genetic Medicines Conference on October 6 at 3:45 PM EDT. The event will be accessible via a live audio webcast on Freeline’s investor relations website, with a replay available for 30 days post-event. Freeline focuses on AAV-based gene therapy targeting liver diseases, aiming to offer potential one-time functional cures for chronic conditions. The company operates in the UK, Germany, and the US, emphasizing its commitment to transforming lives through innovative therapies.
Freeline Therapeutics Holdings (Nasdaq: FRLN) has announced that CEO Theresa Heggie will present at Chardan's 4th Annual Genetic Medicines Conference on October 6, 2020, at 3:45 PM EDT. A live audio webcast of the presentation will be accessible on Freeline's investor relations page, with an archived replay available for 30 days post-conference. Freeline focuses on AAV-based gene therapy for chronic systemic diseases. The company aims to provide one-time treatments for functional cures, operating from the UK, Germany, and the US.
Freeline Therapeutics Holdings plc (Nasdaq: FRLN) has promoted Romuald Corbau, Ph.D., to Chief Scientific Officer. Corbau, who has been with Freeline since 2017, has played a pivotal role in advancing the company's AAV-based gene therapy programs. Founder Amit Nathwani continues as Clinical and Scientific Adviser. Corbau's appointment is expected to enhance the company’s innovative pipeline targeting chronic systemic diseases. His expertise, gained from over 20 years in the pharmaceutical sector, will support Freeline’s mission to leverage gene therapy for transformative patient outcomes.
Freeline Therapeutics Holdings plc (NASDAQ: FRLN) has announced the promotion of Romuald Corbau, Ph.D., to Chief Scientific Officer. He has been pivotal since joining in 2017, significantly contributing to the company's AAV-based gene therapy programs, particularly for Gaucher Disease and Haemophilia A. Founder Amit Nathwani remains as Clinical and Scientific Adviser. With over 20 years of experience, Corbau's leadership is expected to enhance Freeline's innovative pipeline, focusing on providing functional cures for chronic systemic diseases.
Freeline Therapeutics (Nasdaq: FRLN) announced that CEO Theresa Heggie will present at the Chardan Virtual 4th Annual Global Healthcare Conference on October 6 at 4:45 PM EDT. A live audio webcast can be accessed on Freeline's website, along with an archived replay available for 30 days post-conference.
Freeline focuses on AAV-based gene therapy targeting chronic systemic diseases, aiming for functional cures. The company operates in the UK, Germany, and the US.
Freeline Therapeutics (Nasdaq: FRLN) has entered a significant supply agreement with Thermo Fisher Scientific to ensure dedicated production capacity from 2021 to 2027 for its haemophilia B program, FLT180a. This collaboration supports the planned Phase 2b/3 clinical trial and potential commercialization of FLT180a, utilizing Freeline’s proprietary manufacturing processes. The partnership aims to streamline the transition from development to commercialization, with ongoing production capabilities established at Thermo Fisher’s Cambridge facility.
Freeline Therapeutics Holdings plc (Nasdaq: FRLN) announced that CEO Theresa Heggie will participate in a fireside chat at the Morgan Stanley Virtual 18th Annual Global Healthcare Conference on September 15 at 8:00 AM EDT. This event aims to inform investors about Freeline's advancements in AAV-based gene therapy targeting chronic systemic diseases. A live audio webcast will be available on their website, with an archived replay accessible for 30 days post-conference. Freeline focuses on providing transformative gene therapies, primarily targeting liver diseases.
FAQ
What is the market cap of Freeline Therapeutics Holdings plc (FRLN)?
What is Freeline Therapeutics Holdings plc focused on?
What is FLT201?
What are GBA1-linked Parkinson’s disease and Freeline's approach to it?
Where is Freeline Therapeutics headquartered?
What technology does Freeline Therapeutics use for their gene therapies?
What is the significance of the GALILEO-1 trial?
How many people are affected by Gaucher disease?
What are the recent developments in Freeline's FLT201 program?
What was announced in Freeline’s latest financial report?
What is Freeline’s approach to addressing chronic diseases?
